[1]李连第，张思维，鲁凤珠.中国恶性肿瘤死亡谱及分类构成特征研究[J].中华肿瘤杂志, 1997, 第19卷(第5期):323-328 [2]Stark D D, Wittenberg J, Butch R J, et al.Hepatic metastases: randomized,controlled comparison of detection with MR imaging and CT[J].Radiology, 1987, 165(2):399-406 [3]Rummeny E J, Wernecke K, Saini S, et al.Comparison between high-field-strength MR imaging and CT for screening of hepatic metastases: a receiver operating characteristic analysis[J].Radiology, 1992, 182(3):879-886 [4]Semelka R C, Shoenut J P, Kroeker M A, et al.Focal liver disease: comparison of dynamic contrast-enhanced CT and T2-weighted fat-suppressed,FLASH,and dynamic gadolinium-enhanced MR imaging at 15 T[J].Radiology, 1992, 184(3):687-694 [5]Palma L D.Diagnostic imaging and interventional therapy of hepatocellular carcinoma[J].Br J Radiol, 1998, 71(848):808-818 [6]Mahfouz A E, Hamm B, Taupitz M, et al.Hypervascular liver lesions: differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging[J].Radiology, 1993, 186(1):133-138 [7]Frazer C.Imaging of hepatocellular carcinoma[J].J Gastroenterol Hepatol, 1999, 14(8):750-756 [8]Coffin C M, Diche T, Mahfouz A, et al.Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging[J].Eur Radiol, 1999, 9(3):444-449 [9]Burke C, Alexander Grant L, Goh V, et al.The Role of Hepatocyte-Specific Contrast Agents in Hepatobiliary Magnetic Resonance Imaging[J].Seminars in Ultrasound, CT and MRI, 2013, 34(1):44-53 [10]Schuhmann-Giampieri G.Liver contrast media for magnetic resonance imagingInterrelations between pharmacokinetics and imaging[J].Invest Radiol, 1993, 28(8):753-761 [11]Kirchin M A, Pirovano G P, Spinazzi A.Gadobenate dimeglumine (Gd-BOPTA)An overview[J].Invest Radiol, 1998, 33(11):798-809 [12]Schuhmann-Giampieri G, Schmitt-Willich H, Press W R, et al.Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system[J].Radiology, 1992, 183(1):59-64 [13] Dahlstr?m N.Quantitative Evaluation of Contrast Agent Dynamics in Liver MRI[J]. 2010:20-23. [14]Van Beers B E, Pastor C M, Hussain H K.Primovist,Eovist: what to expect?[J].J Hepatol, 2012, 57(2):421-429 [15]Kitao A, Matsui O, Yoneda N, et al.The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging[J].European Radiology, 2011, 21(10):2056-2066 [16]Bellin M.MR contrast agents,the old and the new[J].European Journal of Radiology, 2006, 60(3):314-323 [17]Hamm B, Staks T, Hler A M, et al.Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety,pharmacokinetics,and MR imaging[J].Radiology, 1995, 195(3):785-792 [18]Vogl T J, Kummel S, Hammerstingl R, et al.Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA[J].Radiology, 1996, 200(1):59-67 [19]Hamed M M, Hamm B, Ibrahim M E, et al.Dynamic MR imaging of the abdomen with gadopentetate dimeglumine: normal enhancement patterns of the liver,spleen,stomach,and pancreas[J].AJR. American journal of roentgenology, 1992, 158(2):303-307 [20]Kim H J, Kim B S, Kim M J, et al.Enhancement of the liver and pancreas in the hepatic arterial dominant phase: Comparison of hepatocyte-specific MRI contrast agents,gadoxetic acid and gadobenate dimeglumine,on 3 and 15 tesla MRI in the same patient[J].Journal of Magnetic Resonance Imaging, 2013, 37(4):903-908 [21]Kirchin M A, Pirovano G, Venetianer C, et al.Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance[J].J Magn Reson Imaging, 2001, 14(3):281-294 [22]Reimer P, Schneider G N, Schima W.Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties,clinical development and applications[J].European Radiology, 2004, 14(4):559-578 [23]Reimer P, Rummeny E J, Shamsi K, et al.Phase II clinical evaluation of Gd-EOB-DTPA: dose,safety aspects,and pulse sequence[J].Radiology, 1996, 199(1):177-183 [24].[J]., 2004, 14(4):559-578 [25]Dahlstrom N, Persson A, Albiin N, et al.Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects[J].Acta Radiol, 2007, 48(4):362-368 [26]Smith A D, Veniero J C.Gd-EOB-DTPA as a functional MR cholangiography contrast agent: imaging gallbladder filling in patients with and without hepatobiliary dysfunction[J].J Comput Assist Tomogr, 2011, 35(4):439-445 [27]Tschirch F T C, Struwe A, Petrowsky H, et al.Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma[J].European Radiology, 2008, 18(8):1577-1586 [28]Lee N K, Kim S, Lee J W, et al.Biliary MR imaging with Gd-EOB-DTPA and its clinical applications[J].Radiographics, 2009, 29(6):1707-1724 [29]Bashir M R, Husarik D B, Ziemlewicz T J, et al.Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: Does increasing the flip angle improve conspicuity and detection rate of hypointense lesions?[J].Journal of Magnetic Resonance Imaging, 2012, 35(3):611-616 [30]Kim T K, Lee K H, Jang H J, et al.Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma[J].Radiology, 2011, 259(3):730-738 [31]Tsuboyama T, Onishi H, Kim T, et al.Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation[J].Radiology, 2010, 255(3):824-833 [32]Choi S H, Lee J M, Yu N C, et al.Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI[J].AJR Am J Roentgenol, 2008, 191(2):529-536 [33]Hammerstingl R, Huppertz A, Breuer J, et al.Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions[J].Eur Radiol, 2008, 18(3):457-467 [34]Grazioli L, Morana G, Kirchin M A, et al.Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study[J].Radiology, 2005, 236(1):166-177 [35]Doi N, Tomiyama Y, Kawase T, et al.Focal Nodular Hyperplasia-Like Nodule with Reduced Expression of Organic Anion Transporter 1B3 in Alcoholic Liver Cirrhosis[J].Internal Medicine, 2011, 50(11):1193-1199 [36]Okada M, Ishii K, Numata K, et al.Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function?[J].Hepatobiliary & Pancreatic Diseases International, 2012, 11(3):307-313 [37] 罗宴吉，蔡华崧，汤地，等.肝细胞特异性MR对比剂在肝脏功能评价中的初步研究[J][J].中华消化病与影像杂志(电子版), 2013, 3(05):242-246 [38]Motosugi U, Ichikawa T, Sou H, et al.Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: Which biological markers of the liver function affect the enhancement?[J].Journal of Magnetic Resonance Imaging, 2009, 30(5):1042-1046 [39]廖承德，梁碧玲，钟镜联，等.增强胆道造影在非重度胆道梗阻中的临床应用初探[J].实用放射学杂志, 2010, 26(6):843-846 [40]Gupta R T.Evaluation of the Biliary Tree and Gallbladder With Hepatocellular MR Contrast Agents[J].Current Problems in Diagnostic Radiology, 2013, 42(2):67-76 [41]Lim J S, Kim M J, Kim J H, et al.Preoperative MRI of potential living-donor-related liver transplantation using a single dose of gadobenate dimeglumine[J].AJR Am J Roentgenol, 2005, 185(2):424-431 [42]Krol R, Karkoszka H, Ziaja J, et al.Biliary complications after orthotopic liver transplantation: a 5-year experience[J].Transplant Proc, 2011, 43(8):3035-3038 [43]Masci E, Toti G, Mariani A, et al.Complications of diagnostic and therapeutic ERCP: a prospective multicenter study[J].Am J Gastroenterol, 2001, 96(2):417-423 [44]Fontarensky M, Montoriol P F, Buc E, et al.Advantages of gadobenate dimeglumine-enhanced MR cholangiography in the diagnosis of post-liver transplant bile leakage[J].Diagnostic and Interventional Imaging, 2013, 94(4):443-452 [45]Cieszanowski A, Stadnik A, Lezak A, et al.Detection of active bile leak with Gd-EOB-DTPA enhanced MR cholangiography: Comparison of 20–25min delayed and 60–180min delayed images[J].European Journal of Radiology, 2013, 82(12):2176-2182 [46]Choi I Y, Yeom S K, Cha S H, et al.Diagnosis of biliary stone disease: T1-weighted magnetic resonance cholangiography with Gd-EOB-DTPA versus T2-weighted magnetic resonance cholangiography[J].Clinical Imaging, 2014, 38(2):164-169 [47]宁浩勇，虞积耀.消化系统肿瘤组织学分类[J].诊断病理学杂志, 2011, 18(1):77-79 [48]Wan X.Intraductal papillary neoplasm of the bile duct[J].World Journal of Gastroenterology, 2013, 19(46):8595-8604 [49]Yeh T, Tseng J, Chiu C, et al.Cholangiographic Spectrum of Intraductal Papillary Mucinous Neoplasm of the Bile Ducts[J].Annals of Surgery, 2006, 244(2):248-253 [50] Ohtsuka M, Shimizu H, Kato A, et al.Intraductal Papillary Neoplasms of the Bile Duct[J][J]., 2014, 2014(2014):1-10 [51]Park M, Yu J, Lee D K, et al.Gadobenate dimeglumine–enhanced MRI of intraductal papillary mucinous tumor of the bile ducts[J].Journal of Magnetic Resonance Imaging, 2007, 25(3):625-627 [52]Ergen F B, Akata D, Sarikaya B, et al.Visualization of the biliary tract using gadobenate dimeglumine: preliminary findings[J].J Comput Assist Tomogr, 2008, 32(1):54-60 [53]Wu Z, Matsui O, Kitao A, et al.Usefulness of Gd-EOB-DTPA-enhanced MR imaging in the evaluation of simple steatosis and nonalcoholic steatohepatitis[J].Journal of Magnetic Resonance Imaging, 2013, 37(5):1137-1143 [54]Williams R.Global challenges in liver disease[J].Hepatology, 2006, 44(3):521-526 [55] 袁平戈.非酒精性脂肪性肝病的诊断和治疗探讨[J]., 2009(02):333-336.[J].西部医学, 2009, 2(21):333-336 [56]Tsuda N, Okada M, Murakami T.New proposal for the staging of nonalcoholic steatohepatitis: Evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI[J].European Journal of Radiology, 2010, 73(1):137-142 [57]Bastati N, Feier D, Wibmer A, et al.Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study[J].Radiology, 2014, 271(3):739-747 [58]Tsuda N, Okada M, Murakami T.Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging[J].Invest Radiol, 2007, 42(4):242-247